At Apostle, we aim to develop technologies to fundamentally improve the efficiency and accuracy of liquid biopsy in early cancer detection.

Vision


The best predictive measure of the success of cancer treatment, universally for all forms of cancer, is how early the cancer is detected. At any size, tumors begin to rapidly shed DNA in blood circulation. Apostle is developing a technique to capture this circulating tumor DNA from a standard blood draw to help inform doctors if a patient is likely to have early stages of cancer, what form the cancer is in, and what treatment may be most successful against it. This will greatly benefit the entire population, as cancer is the leading cause of death globally.

We are positioning our company to be the pioneer in field of early cancer detection through blood-based liquid biopsy testing. Our ultimate vision is to develop an AI-enabled diagnostic system, using patent-pending nanoparticles reagents, that can use a standard blood draw to detect ultra-low levels of circulating tumor DNA, then use a best-in-class bioinformatics platform that plucks out hidden signatures to detect cancer at an earlier stage than is currently possible. This vision is feasible thanks to the 10x higher efficiency of our nanoparticle reagents as well as the AI-system that compares and learns from cancer big data.

In addition, our high-sensitivity technology can be used in a broad spectrum of clinical applications such as noninvasive prenatal testing (NIPT) and infectious diseases.

1. Apostle MiniMaxTM Technology




Apostle MiniMaxTM technology offers a revolutionary 10%-10X higher efficiency to capture and isolate the circulating cell-free genetic materials.

The ability to isolate and analyze circulating cell free DNA (cfDNA) at very low concentrations is becoming increasingly important, particularly in non-invasive prenatal test, early cancer detection, and infectious disease diagnosis. Highly efficient isolation of cfDNA from complexed biological medium is a crucial step for subsequent cfDNA analysis.

Products Cat# User manual Order online
Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit (Standard Edition) (25-50 preps) A17622-50 minimax_protocol_v17_25-50_preps.pdf Order
Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit (Standard Edition) (5-10 preps) A17622-10 minimax_protocol_v17_5-10_preps.pdf Order
Apostle MiniMaxTM High Efficiency Magnetic Nanoparticles (Standard Edition) (5mL) A320 Order
Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit (Type S) (25-50 preps) A17830-50 minimax_type_S_protocol_v7_25-50_preps.pdf Order
Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit (Type S) (5-10 preps) A17830-10 minimax_type_S_protocol_v7_5-10_preps.pdf Order
Apostle MiniMaxTM High Efficiency Magnetic Nanoparticles (Type S) (5mL) A321 Order
MiniMax data image
  • Exhibit 1-1. Apostle’s proprietary MiniMax magnetic nanoparticles. The Apostle MiniMax nanoparticles have an increased magnetic strength and a decreased particle size compared to other leading technologies in the market, which ensures excellent suspension in solution and rapid mobility. The optimized surface chemistry allows efficient enrichment of genetic materials from complex biological materials.


Apostle MiniMax technology ensures precise capture and separation of circulating genetic materials for liquid biopsy analysis. This is achieved through Apostle’s novel proprietary MiniMax magnetic nanoparticles (Exhibit 1-1, 1-2) with novel material composition and surface chemistry, large surface area and minimized variation.

MiniMax data image
  • Exhibit 1-2. Apostle’s proprietary MiniMax nanoparticles have uniform sizes. Apostle’s MiniMax magnetic nanoparticles generated from our proprietary technology have a uniform size distribution with minimized doublets, distinct from the particles from five current technological providers showing random sizes and significant doublets. Highly consistent size distribution of Apostle’s nanoparticles ensure reproducible results.
  • Exhibit 1-3 (YouTube Video). The Apostle MiniMax nanoparticles have a best-in-class suspension property.
    Excellent suspension is one of the critical properties of nanoparticles to excel in cfDNA isolation. In this simple but quite visual experiment, we compare Apostle MiniMax with the nanoparticles from other two technologies on the market. The three tubes contain equal weight of different types of nanoparticles.
MiniMax data image
  • Exhibit 1-4. The three tubes contain equal weight of different types of nanoparticles. By 1 minute, the other technology #2 is almost completely sedimented. By 15 minute, the other technology #1 is almost completely sedimented. However, Apostle MiniMax has kept the suspension status, showing a superb suspension property.
  • Exhibit 1-5 (YouTube Video). The Apostle MiniMax nanoparticles have a best-in-class magnetic power.
    A strong magnetic power is another critical property of nanoparticles to achieve a good cfDNA isolation performance. In this simple experiment, we compare the magnatic power of Apostle MiniMax with the nanoparticles from other two technologies on the market. The three tubes contain equal weight of different types of nanoparticles. A magnetic plate slowly approaches the three tubes at equal distances. Whichever tube having the strongest magnetic power makes the first move.
    The tube containing Apostle MiniMax makes the first move, while the other two technologies stay still. Apostle MiniMax shows a superb magnetic power.
MiniMax data image
  • Exhibit 1-6. The three tubes contain equal weight of different types of nanoparticles. A magnetic plate slowly approaches the three tubes at equal distances. Whichever tube having the strongest magnetic power makes the first move.
    The tube containing Apostle MiniMax makes the first move, while the other two technologies stay still. Apostle MiniMax shows a superb magnetic power.

MiniMax data image
  • Exhibit 1-7. The Apostle MiniMax nanoparticles have a superb resistance to particle clustering.
    The unwanted clustering of particles reduces the performance of the cfDNA isolation, and sometimes even interferes with the normal lab procedures. In this experiment, we compare MiniMax's ability to resist clustering with another leading technology on the market. After adding isopropyl alcohol, the other technology shows particle clustering visible to naked eye, while Apostle MiniMax does not. The Apostle MiniMax nanoparticles show a superb resistance to particle clustering.

    >click for here a high-resolution picture

2. Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit (Standard Edition)


MiniMax data image


Products Cat# User manual Order
Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit (Standard Edition) (25-50 preps) A17622-50 minimax_protocol_v17_25-50_preps.pdf Order online
Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit (Standard Edition) (5-10 preps) A17622-10 minimax_protocol_v17_5-10_preps.pdf Order online
Apostle MiniMaxTM High Efficiency Magnetic Nanoparticles (Standard Edition) (5mL) A320 Order


Powered by Apostle MiniMax technology, Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit is an excellent tool for the isolation of ultra-low concentration cell free DNA (cfDNA). Compared to major alternative suppliers, Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit offers superior DNA isolation efficiency for DNA ladders spiked in different biological medium (Exhibit 2-1).

MiniMax data image
  • Exhibit 2-1. Superior DNA isolation efficiency.

    A) DNA ladder (50-3000bp) was spiked in TE buffer, followed by isolation with Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit (red curve) and major alternative product (blue curve). The isolated DNA was characterized by Bioanalyzer 2100.

    B) DNA ladder was spiked in serum, followed by isolation with Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit (red curve) and major alternative product (blue curve). The isolated DNA was characterized by Bioanalyzer 2100. Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit offers superior DNA enrichment efficiency of 110% – 10x.


Over 95% DNA recovery in range between 80 – 3000bp was achieved using Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit, as demonstrated through recovery of DNA ladder spiked in serum (Exhibit 2-2). This is due to the optimal interaction between DNA and the nanoparticles enabled by the MiniMax technology, resulting in efficient binding with cfDNA in complexed biological medium and total elution of cfDNA at later stage.

MiniMax data image
  • Exhibit 2-2. Over 95% DNA recovery in range between 80 – 3000bp. DNA ladder was spiked in serum, followed by isolation with Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit. The Isolated DNA was characterized by Bioanalyzer 2100 (red curve), and compared with original DNA ladder (blue curve). Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit offers superior DNA recovery efficiency of > 95%.


The Apostle MiniMaxTM High Efficiency cfDNA Isolation Kits are manufactured under highly controlled and validated production processes. This will ensure optimal performance with high efficiency and reproducibility in cfDNA isolation (Exhibit 2-3).

MiniMax data image
  • Exhibit 2-3. Highly reproducible DNA isolation process. DNA ladder was spiked in serum, followed by isolation with three batches of Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit. The Isolated DNA was characterized by Bioanalyzer 2100, and compared between batches. Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit offers highly consistent DNA isolation result.


cfDNA is a group of highly fragmented DNA molecules, with major peak at ~170bp, doublet peak at ~340bp, triplet peak at ~510bp, and so on. Therefore, cfDNA isolation kit capable of highly efficient cfDNA isolation spanning wide cfDNA size distribution is desired. Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit meets such need as demonstrated from its > 95% recovery of DNA ladder. This is further validated through isolation of natural cfDNA from human plasma (Exhibit 2-4A) and urine samples (Exhibit 2-4B), where Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit offers superior cfDNA isolation efficiency over wide range, specifically covering the 170bp, 340bp, and 510bp cfDNA peaks, when compared with major alternative product. 

MiniMax data image
  • Exhibit 2-4. Superior natural cfDNA isolation efficiency in human plasma and urine.

    A) Cell-free plasma was separated from blood samples by centrifugation for 10 minutes at 2000g at 4 oC, then centrifuged for 10 minutes at 16000g at 4 oC. cfDNA was isolated from 4mL plasma with Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit (red curve) and major alternative product (blue curve). The isolated cfDNA was characterized by Bioanalyzer 2100.

    B) Cell-free urine was prepared by centrifugation for 10 minutes at 16000g at 4 oC. cfDNA was isolated from 20mL urine with Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit (red curve) and major alternative product (blue curve). The isolated cfDNA was characterized by Bioanalyzer 2100. Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit offers superior cfDNA isolation efficiency for both plasma and urine samples.


Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit enables superior and consistent performance of DNA mutation detection, validated by qPCR (Exhibit 2-5).

MiniMax data image
  • Exhibit 2-5. Superior performance of DNA mutation detection isolated with Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit

    20 uL of DNA fragment containing the EGFR c.2573T>G L858R mutation (synthetic, ~170 bp), with concentration of 1 ng/uL, 0.1 ng/uL, 0.01 ng/uL, 0.001 ng/uL, was spiked into 1mL TE buffer (blue) or Serum (red) respectively. The mutated DNA fragment was isolated with Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit (Standard Edition), with a final elution volume of 20 uL. qPCR was performed using 1 uL of the isolated DNA, and compared with 1 uL of the corresponding original mutated DNA solution at 1 ng/uL, 0.1 ng/uL, 0.01 ng/uL, 0.001 ng/uL.

    A) Amplification plot showing highly overlapping curves for mutated DNA fragment isolated with Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit and original DNA solution at different concentrations.

    B) qPCR standard curve generated using original mutated DNA solution, in order to quantify the recovery of DNA isolated with Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit. DNA isolation recovery rate was calculated to be >90%.

    Note: Displayed DNA concentration series at 1, 0.1, 0.01, 0.001 ng/ul are the concentrations of the original DNA dilution series before spiking into 1mL of serum. The corresponding DNA isolation working concentrations are 20 pg/ul, 2 pg/ul, 0.2 pg/ul, 0.02 pg/ul, respectively.

3. Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit (Type S)

– designed for small DNA fragments (<100bp)


MiniMax data image


Products Cat# User manual Order
Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit (Type S) (25-50 preps) A17830-50 minimax_type_S_protocol_v7_25-50_preps.pdf Order online
Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit (Type S) (5-10 preps) A17830-10 minimax_type_S_protocol_v7_5-10_preps.pdf Order online
Apostle MiniMaxTM High Efficiency Magnetic Nanoparticles (Type S) (5mL) A321 Order


Powered by Apostle MiniMax technology, Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit (Type S) is an excellent tool for the isolation of ultra-low concentration cell free DNA (cfDNA). Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit (Type S) is featured for its efficient recovery of small DNA fragments (<100 bp) from biological samples (Exhibit 3-1 & 3-2). This feature is quite useful when small DNA molecules have significant presence in the biological sample and need to be isolated (Exhibit 3-1).

MiniMax data image
  • Exhibit 3-1. Over 95% DNA recovery in range between 50 – 3000bp.

    DNA ladder was spiked in serum, followed by isolation with Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit (Type S). The Isolated DNA was characterized by Bioanalyzer 2100 (red curve), and compared with original DNA ladder (blue curve). Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit offers superior DNA recovery efficiency of >95%, including small DNA fragments at~50bp as highlighted.


Compared to major alternative suppliers with magnetic bead technology, Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit (Type S) offers superior DNA isolation efficiency for cfDNA reference spiked in biological medium, especially for cfDNA with size < 80bp (Exhibit 3-2).

MiniMax data image
  • Exhibit 3-2 . Superior small DNA isolation efficiency.

    A) cfDNA reference standard (Horizon Discovery Ltd, Cat# HD780) was spiked in TE buffer, followed by isolation with Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit (Type S). The isolated DNA was characterized by Bioanalyzer 2100 (red curve), and compared with original cfDNA reference standard (blue curve). Apostle MiniMaxTM High Efficiency cfDNA Isolation Kit (Type S) offers >95% recovery of the cfDNA reference standard, which has significant portion of DNA fragments with size < 100bp.
MiniMax data image
  • Exhibit 3-2. Superior small DNA isolation efficiency.

    B) cfDNA reference standard was spiked in TE buffer, followed by isolation with MiniMaxTM Type S and a major alternative product. Bioanalyzer 2100 analysis demonstrated significantly higher cfDNA recovery rate of MiniMaxTM Type S (red curve) compared to a major alternative product (blue curve).
MiniMax data image
  • Exhibit 3-2. Superior small DNA isolation efficiency.

    C) Zoom in of B)in the region between 35bp – 100 bp. MiniMaxTM Type S (red curve) is compared to a major alternative product (blue curve). Bioanalyzer 2100 analysis demonstrated the efficient recovery at ~50bp of MiniMaxTM Type S (red curve), while a major alternative product (blue curve) failed.

4. Apostle TritonTM Liquid Biopsy Machine-Learning Framework


Apostle TritonTM AI Technology learns from a curated internal cancer database of 30,000 patients with an unprecedented resolution.

Why do we need machine-learning in a liquid biopsy technology?

  • Cancer is a genetically heterogeneous disease.
  • Somatic mutations exist in both cancer and normal cells.
  • We still know very little about the genetics of cancer. There is a lacking of a comprehensive and coherent way to mine the big data repository of cancer genetics and apply the applicable findings.
  • The clinical application of liquid biopsy is further complicated by the characteristics of cell free tumor nucleic acids: low concentration, complex fragmentation, etc.



Here, we introduce TRITON, a deep-learning framework designed for liquid biopsy, which learns from cancer genomic big data, evaluates disease effects of somatic mutations/variants and expression signatures, and apply the findings in the settings of liquid biopsy.

Independent Evaluation Reports


"We have never seen a better technology. Apostle MiniMax is the only one that we have found to perform significantly better than other cfDNA extraction methods that we have used and refined for years, delivering significantly higher yield that is critical for NIPT and liquid biopsy."

- Anders Nygren, PhD, Clinical Genetics
  Sr Director, R&D
  Agena Biosciences


An independent evaluation report shows Apostle MiniMax High Efficiency cfDNA Isolation Kit (Standard Edition) has a 12% higher efficiency than a competing older technology.

Download independent evaluation report

Disclaimer: 1) Apostle was not involved in the experimental design and execution of this independent evaluation. 2) This evaluation used an off-protocol method, which is not typically recommended by Apostle. Please follow our protocols.

Team


David Ge, MD. PhD.CEO & President

  • 18+ years of research and industry experience in genomic sciences
  • U.S. Citizen through federal "Outstanding Professors and Researchers"
  • President of BioSciKin Co. & Simcere Diagnostics Co (2016-2017)
  • Director of Bioinformatics at Gilead Sciences, Inc (2011-2016)
  • Assistant Professor of Biostatistics & Bioinformatics, Duke University School of Medicine (2008-2011)
  • Ph.D. in Biostatistics & Genetic Epidemiology, CAMS & PUMC (2004)
  • Co-authored 70+ peer-reviewed papers, 5 in Nature and 1 in Science, over 16,000 citations.

Bo Zhang, PhD.VP of Chemistry

Xin Guo, PhD.VP of Bioinformatics

  • 10+ years of research and industry experience in bioinformatics, artificial intelligence (AI), and HPC
  • VP of Bioinformatics, Simcere Diagnostics, Inc (2016-2017)
  • Group leader, research scientist of Bioinformatics at Gilead Sciences, Inc. Led the clinical phylogenomic project for Sovaldi®, a world-leading anti-HCV drug. (2012-2016)
  • Ph.D. in Computer Science, Duke University (2012)
  • M.S. in Informatics from Max Planck Institute, Germany (2006)
  • Led multiple publications in AI, including in PNAS.

Wenqi Zeng, MD. PhD. FACMG.Chief Medical Advisor

  • 15+ years of research, clinics and industry experience in clinical diagnostics
  • Senior director of Molecular Genetics at Quest Diagnostics (2014-2017)
  • Director of Clinical Genomics at Ambry Genetics (2011-2014)
  • Qualified CAP CLIA lab director in CA, FL and MD; Qualified CAP inspection team leader
  • New York state COQ in molecular genetics and molecular oncology
  • PhD, Molecular Genetics
  • Fellow of clinical molecular genetics, human/medical genetics, Harvard Medical School
  • Holding diploma of ABMGG

Shuting Zhao, PhDScientist

  • 5+ years research experience in micro and nano scale biomaterials and their applications on regenerative medicine, cancer treatment, drug delivery and drug screening
  • PhD in Biomedical Engineering, Ohio State University
  • MS in Biomedical Engineering, Cornell University
  • First-author article in Nature Communications
  • 19 co-authored peer-reviewed publications in top journals and one US patent
  • HHMI Med into Grad Scholar in Ross Heart Hospital

Joshua Robinson, PhDPrincipal Business Development Consultant

  • Innovation Leader, Colox, a Fortune 500 Consumer Packaged Goods company
  • Director, Nirmidas Biotech, Inc., a point-of-care diagnostic company
  • Senior Application Scientist, Beckman Coulter, an American company that develops, manufactures and markets products for complex biomedical testing in both diagnostics and life sciences laboratories .
  • Principal investigator, NIH R43 grant
  • PhD, Stanford University
  • BS, Purdue University

Advisory Board


Charles Cantor, PhD.

  • Member of National Academy of Sciences
  • Professor Emeritus, Biomedical Engineering, Boston University
  • Founder & Chief Scientific Officer at Sequenom, Inc. (NASDAQ: SQNM, acquired by LabCorp)
  • Chairman, Department of Biomedical Engineering, Boston University
  • Director, Center for Advanced Biotechnology, Boston University
  • Director, the Human Genome Project (HGP)
  • Ph.D., Biophysical Chemistry, University of California, Berkeley
  • A.B., Chemistry, Columbia University

Hongyu Zhao, PhD.

  • Chairman, Biostatistics Department, Yale University
  • Ira V. Hiscock Professor of Biostatistics and Professor of Statistics and Genetics, Yale University
  • Fellow, AAAS (American Association for the Advancement of Science)
  • Fellow, Institute of Mathematical Statistics
  • Fellow, American Statistical Association
  • Ph.D., Statistics, University of California at Berkeley
  • B.S., Probability and Statistics, Peking University

Dean Felsher, MD. PhD.

  • Professor. Division of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine
  • Director, Translational Research and Applied Medicine; Director of Research, Division of Oncology; Associate Director, Director of Admissions, Medical Scientist Training Program (MSTP); Co-Director, Translational Cancer Nanotechnology Training Program; Stanford University School of Medicine
  • Elected Member, Association of American Physicians
  • M.D. Ph.D., Medicine/Molecular Biology, UCLA
  • B.S., Chemistry, University of Chicago

Board of Directors


David Ge, MD. PhD.Chairman

William Dai, MBADirector

Bo Zhang, PhD.Director

Xin Guo, PhD.Director

News & Tweets


2017
DEC
08
Apostle Inc and Filgen Inc Announce Supply and Distribution Agreement in Japan
Apostle Inc is pleased to announce the signing of an agreement with Filgen Inc to supply and distribute Apostle’s technological products exclusively in Japan. read more
2017
SEP
19
Apostle Inc Won the Second Place in the Final of North America Region, CACSC
Apostle won the Second Place in the Final of North America Region, CACSC,(Create@AlibabaCloud Startup Contest). Over 300 startups from North America have competed in CACSC, and 13 entered the final. read more
2017
SEP
1
Apostle Inc Appoints Director of Oncology Research at Stanford University to Scientific Advisory Board
Apostle Inc is pleased to announce the appointment of Dean W. Felsher, MD, PhD as a new member to its Scientific Advisory Board. Dr. Felsher is Professor of Medicine in Departments of Oncology and Pathology at Stanford University School of Medicine. He is Director of Stanford Translational Research and Applied Medicine (TRAM) as well as Director of Oncology Research, Division of Oncology at Stanford. read more
2017
AUG
28
Apostle Inc Is Selected by the Amazon Web Service Activate Program
Apostle Inc is selected into the Amazon Web Service (AWS) Activate Program. The AWS Activate Portfolio Package received by Apostle includes a one-year AWS Gold Premium Support and a two-year AWS usage credit. read more
2017
JUL
20
Forbes China Named Bo Zhang, Co-Founder and VP of Apostle Inc, as One of the Most Brilliant Young Entrepreneurs Under 30
Forbes China named Apostle Inc’s co-Founder and VP of Chemistry, Bo Zhang, PhD, as one of the most brilliant young entrepreneurs in its annual “30 Under 30 China” list in the category of healthcare and science. read more
2017
JUN
16
Apostle Announces New Board Member And Advisors
Apostle Inc is pleased to announce the appointment of William Dai, MBA as a new member to its Board of Directors, and Charles Cantor, PhD and Hongyu Zhao, PhD as new members to its Advisory Board. read more
2017
APR
14
Apostle Inc Presents at the 7th Asia Pharma R&D Leaders 2017
Apostle Inc today led a round-table discussion at the 7th Asia Pharma R&D Leaders 2017, held in Shanghai, China. read more
2017
APR
08
Apostle CEO is invited to join the Advisory Board of the 13th Annual Biomarkers Congress 2018
Apostle CEO David Ge is invited to be on the Advisory Board of the 13th Annual Biomarkers Congress, organized by the Oxford Global and to be held in February 2018 in Manchester, UK. read more
2017
MAR
28
Apostle Inc is founded
Apostle Inc, a biotechnology company developing an AI-enabled nanoDiagnostics (AID) technology for early cancer detection, is founded in the Silicon Valley. read more

Investors